Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial The objective response rate in advanced melanoma was 62.5% (five of eight subjects)

Saved in:
Bibliographic Details
Published inNASDAQ OMX's News Release Distribution Channel
Format Newsletter
LanguageEnglish
Published New York NASDAQ OMX Corporate Solutions, Inc 13.11.2017
Subjects
Cancer therapies
Clinical trials
Drug dosages
Head & neck cancer
Immunotherapy
Laboratories
Liver cirrhosis
Liver diseases
Melanoma
Metastasis
Proteins
Research centers
Response rates
Online AccessGet full text

Cover

More Information
Description not available.